(-)-Blebbistatin: Precision Non-Muscle Myosin II Inhibitor for Cytoskeletal Dynamics Research

Executive Summary: (-)-Blebbistatin (CAS 856925-71-8) is a selective, reversible, and cell-permeable inhibitor of non-muscle myosin II (NM II), acting by suppressing Mg-ATPase activity and actomyosin-mediated contractility at low micromolar concentrations (APExBIO). It exhibits minimal activity against myosin isoforms I, V, X, and smooth muscle myosin II at relevant concentrations, supporting its specificity (Rashid et al., 2025). (-)-Blebbistatin enables high-fidelity research into cytoskeletal dynamics, mechanotransduction, and disease modeling, including MYH9-related experiments and cardiac contractility studies (related article). The compound’s solubility and handling parameters, such as optimal dissolution in DMSO and temperature sensitivity, are critical for reproducible results. Recent work demonstrates that actomyosin inhibition via (-)-Blebbistatin blocks mechanical stress-induced YAP nuclear translocation, confirming its utility in mechanomemory and cytoskeletal signaling assays (DOI).

Biological Rationale

Non-muscle myosin II (NM II) is an actin-dependent ATPase essential for cell adhesion, migration, and differentiation (Rashid et al., 2025). NM II orchestrates actomyosin contractility, which underpins cytoskeletal organization, tissue morphogenesis, and mechanotransduction. Dysregulation of NM II function is implicated in cancer progression, MYH9-related diseases, and cardiac disorders. Small-molecule NM II inhibitors like (-)-Blebbistatin enable precise, reversible interrogation of actin-myosin interactions, providing key insights into cell mechanics, signal transduction, and force-responsive gene expression. Recent studies confirm that actomyosin contractility is required for nuclear localization of YAP, a transcriptional co-regulator central to mechanomemory and cell fate decisions (DOI).

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin binds selectively to the myosin-ADP-phosphate complex and inhibits the release of inorganic phosphate, thereby suppressing Mg-ATPase activity in NM II (APExBIO). This inhibition is reversible and concentration-dependent, with an IC₅₀ between 0.5 and 5.0 μM for NM II. The compound exhibits minimal effects on myosin I, V, and X isoforms at these concentrations, and only weakly inhibits smooth muscle myosin II (IC₅₀ ≈ 80 μM). By blocking actomyosin contractility, (-)-Blebbistatin prevents downstream mechanical signaling, including the nuclear translocation of YAP/TAZ and expression of mechanosensitive genes (e.g., CTGF) (Rashid et al., 2025). The specificity and reversibility of (-)-Blebbistatin make it a robust tool for dynamic studies of cytoskeletal regulation.

Evidence & Benchmarks

• (-)-Blebbistatin inhibits non-muscle myosin II with an IC₅₀ of 0.5–5.0 μM under cell-based conditions (APExBIO).
• The compound shows minimal inhibition of myosin I, V, and X at ≤10 μM, confirming high selectivity (APExBIO).
• Exposure to (-)-Blebbistatin blocks actomyosin-driven YAP nuclear translocation in response to intermittent mechanical stress (Rashid et al., 2025).
• In zebrafish embryos, (-)-Blebbistatin induces dose-dependent cardia bifida, highlighting its developmental biology utility (APExBIO).
• Stock solutions are stable in DMSO (≥14.62 mg/mL) at -20°C for several months, with recommended use of freshly prepared working solutions (APExBIO).
• Mechanotransduction studies demonstrate that (-)-Blebbistatin, but not microtubule inhibitors, abolishes stress-induced F-actin increase and YAP translocation (Rashid et al., 2025).

Applications, Limits & Misconceptions

(-)-Blebbistatin is widely used to dissect actomyosin contractility in cell mechanics, cancer biology, and cardiac research. It enables temporally precise inhibition in live-cell imaging, mechanotransduction assays, and developmental models. For example, in studies of mechanomemory, (-)-Blebbistatin is essential for demonstrating that F-actin and myosin II activity are required for YAP-mediated gene regulation following mechanical stress (DOI). Cardiac muscle studies use (-)-Blebbistatin to modulate contractility without affecting electrical activity, supporting research into arrhythmogenesis and heart disease.

This article extends prior coverage in "Harnessing (-)-Blebbistatin for Cytoskeletal Dynamics Research" by providing new evidence from 2025 on mechanomemory and YAP signaling. It clarifies the selectivity and reversibility benchmarks outlined in "(-)-Blebbistatin: Transforming Non-Muscle Myosin II Research", and updates the translational discussion in "Translational Traction: Harnessing (-)-Blebbistatin to Decode Mechanomemory" by highlighting YAP/CTGF axis modulation.

Common Pitfalls or Misconceptions

• (-)-Blebbistatin is ineffective against smooth muscle myosin II at standard concentrations (IC₅₀ ≈ 80 μM); do not use for smooth muscle-specific studies (APExBIO).
• The compound is insoluble in water and ethanol; always dissolve in DMSO and use ultrasonic treatment if necessary.
• Photo-instability: (-)-Blebbistatin degrades under blue/UV light; protect from light during handling and storage.
• Reversibility: Washout is required for functional recovery; incomplete removal may prolong inhibition.
• Not a pan-myosin inhibitor: (-)-Blebbistatin does not inhibit myosin I, V, or X at research-relevant doses.

Workflow Integration & Parameters

Researchers typically prepare (-)-Blebbistatin stock solutions in DMSO at ≥14.62 mg/mL, storing aliquots at -20°C for long-term stability (APExBIO). For experimental use, working solutions are freshly prepared and protected from light. Optimal inhibitory concentrations for NM II are 0.5–5.0 μM, with higher doses required for partial smooth muscle inhibition. Solubility is enhanced by warming and sonication. Timing and reversibility allow for acute or chronic studies of actomyosin function. (-)-Blebbistatin is compatible with live-cell imaging, traction force microscopy, and gene expression assays such as qPCR for CTGF (Rashid et al., 2025).

Conclusion & Outlook

(-)-Blebbistatin remains a gold standard for selective, reversible inhibition of non-muscle myosin II, underpinning major advances in cytoskeletal dynamics, mechanotransduction, and disease modeling research. Ongoing studies, such as those revealing its role in blocking YAP nuclear translocation during mechanomemory, reinforce its unique value in dissecting actomyosin-mediated signaling. As new mechanomedicine paradigms emerge, (-)-Blebbistatin from APExBIO will continue to support rigorous, reproducible insights into cell adhesion, migration, cardiac physiology, and cancer progression. For detailed protocols, storage, and ordering, see the (-)-Blebbistatin B1387 product page.